Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
出版年份 2021 全文链接
标题
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
作者
关键词
-
出版物
Gastric Cancer
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-04
DOI
10.1007/s10120-021-01168-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers
- (2020) A. Yver et al. ANNALS OF ONCOLOGY
- Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
- (2020) Seiichiro Mitani et al. Cancers
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
- (2020) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
- (2020) Zhi Peng et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.
- (2019) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- (2019) Kohei Shitara et al. LANCET ONCOLOGY
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
- (2018) Hiroshi Saeki et al. EUROPEAN JOURNAL OF CANCER
- Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer
- (2018) Alexis D. Leal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
- (2016) Hongwen Li et al. CANCER BIOLOGY & THERAPY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
- (2016) Federica Grillo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases
- (2016) Xiaoyan Liu et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
- (2015) Xuejing Yao et al. BREAST CANCER RESEARCH AND TREATMENT
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started